Hong Kong stock market anomaly | PegBio Medicine-B(02565.HK) surged more than 12% at the closing bell, its core product Vepinavir injection approved for listing.

According to the Securities Times app, BeiGene Biopharmaceuticals-B (02565.HK) rose more than 12% in the final trading session. As of the time of publication, it rose by 12.59%, reaching 63.5 Hong Kong dollars, with a transaction volume of 28.2011 million Hong Kong dollars.